Phase III
Swiss pharma giant Novartis will launch a Phase III trial assessing hydroxychloroquine for the treatment of COVID-19. The trial will be conducted across the United States.
Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have.
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
A recent study published in JAMA Oncology found that although about a third of cancer clinical trials failed to meet their primary endpoints, at oncology meetings they tend to be spun in a positive light.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 17, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
Gilead said that the Phase III trial for mild to moderate patients had been ended because of lack of patients to enroll.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 15, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
A preliminary analysis of late-stage trial data shows that BeiGene’s investigational checkpoint inhibitor tislelizumab is hitting the mark as a potential first-line treatment in patients with non-squamous non-small cell lung cancer.
PRESS RELEASES